RAPP
Rapport Therapeutics, Inc. Common Stock
NASDAQ · USHealthcareBiotechnology
$40.21-5.65%
Price as of Jul 20, 2026
RAPP profitability
Rapport Therapeutics, Inc. Common Stock profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 96.3%
- EBITDA margin
- -590.7%
- EBIT margin
- -611.0%
- Net margin
- -536.4%
- Free cash flow margin
- -403.5%
Returns
- Return on equity
- -22.8%
- Return on assets
- -21.6%
- Return on invested capital
- -25.3%
- Asset turnover
- 0.04x
Cash efficiency
- Cash from operations
- -$80.3M
- Cash per share
- $9.97
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.